Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
to learn if giving glofitamab after treatment with BTKi-rituximab can help to control high-risk MCL.
Confirmed diagnosis of mantle cell lymphoma by hematopathology. MCL should have... [+3]
Isolated bone marrow or GI only disease MCL participants and/or lack of any meas... [+43]